-
1.发明申请APPLICATION OF SP PEPTIDE OR DERIVATIVE THEREOF IN PREPARING MEDICINES FOR PREVENTING OR TREATING ASTHMA 有权SP肽或其衍生物在制备用于预防或治疗哮喘的药物中的应用公开(公告)号：US20150284430A1
公开(公告)日：2015-10-08
申请号：US14742656
申请日：2015-06-17
发明人： YUN CHENG , Ruihe Yu , Hong Li , Wanzhou Zhao
IPC分类号： C07K7/06
摘要： The present invention provides an application of an SP peptide or a derivative thereof in preparing medicines for preventing or treating asthma. The peptide or the derivative thereof is the SP peptide shown in Formula I or a pharmaceutically acceptable salt or ester thereof. The present invention also provides a method for treating asthma, the method comprises: administering to a patient with medicine containing the peptide or the derivative thereof with an effective therapeutic dosage. It proves through researches of the present invention that, the peptide or the derivative thereof can effectively alleviate pathological symptoms of asthma, especially pathological symptoms of allergic asthma. In the formula (I), Xaa1 is deletion, Ala, Gly, Val, Leu or Ile; Xaa2 is Thr or Ser; Xaa3 is Tyr, Phe or Trp; and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (Formula I)
摘要翻译： 本发明提供SP肽或其衍生物在制备用于预防或治疗哮喘的药物中的应用。 肽或其衍生物是式I所示的SP肽或其药学上可接受的盐或酯。 本发明还提供了一种治疗哮喘的方法，所述方法包括：以有效的治疗剂量向含有所述肽或其衍生物的药物给予患者。 通过本发明的研究证明，肽或其衍生物可以有效缓解哮喘的病理症状，特别是过敏性哮喘的病理症状。 在式（I）中，Xaa1是缺失型，Ala，Gly，Val，Leu或Ile; Xaa2是Thr或Ser; Xaa3是Tyr，Phe或Trp; 并且Xaa4是缺失型，Ala，Gly，Val，Leu，Ile或Pro。 Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4（式I）
-
公开(公告)号：US09605023B2
公开(公告)日：2017-03-28
申请号：US14742656
申请日：2015-06-17
发明人： Yun Cheng , Ruihe Yu , Hong Li , Wanzhou Zhao
摘要： The present invention provides an application of an SP peptide or a derivative thereof in preparing medicines for preventing or treating asthma. The peptide or the derivative thereof is the SP peptide shown in Formula I or a pharmaceutically acceptable salt or ester thereof. The present invention also provides a method for treating asthma, the method comprises: administering to a patient with medicine containing the peptide or the derivative thereof with an effective therapeutic dosage. It proves through researches of the present invention that, the peptide or the derivative thereof can effectively alleviate pathological symptoms of asthma, especially pathological symptoms of allergic asthma. In the formula (I), Xaa1 is deletion, Ala, Gly, Val, Leu or Ile; Xaa2 is Thr or Ser; Xaa3 is Tyr, Phe or Trp; and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (Formula I)
-
搜索结果
2 条记录 (耗时 0.014 秒)
